Research Title: A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Realted Macular Degeneration.
Sponsor: Regeneron Pharmaceuticals
Principal Investigator: Michael Jacobson, M.D.
Description: The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
Start Date: July 2016
Project Personnel: Leslie Marcus, CCRC; Caitlin Harrison, CCRC, COA; Halie Sklanka, CRC
Location(s): Tucker; 1462 Montreal Road West, Suite 412, Tucker, GA 30084